30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now

Bill Bertrand

Track

Insider profile

Currently holds positions in Adaptimmune Therapeutics PLC, Medimmune LLC and Ardelyx Inc

Performance

Overall performance
3.5
Performance over holding periods
3.5
30 days 90 days 120 days
Average return -9% 8.2% 15.1%
Success rate 61% 68% 82%
Transactions
22 0% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Chief Operating Officer Adaptimmune Therapeutics PLC March 15, 2017 -
Executive Vice President, General Counsel Medimmune LLC None -
Independent Director Ardelyx Inc Oct. 26, 2015 -
Executive Vice President, General Counsel Infinity Pharmaceuticals Inc Oct. 19, 2015 - Sept. 2, 2016
Acting Chief Operating Officer Salix Pharmaceuticals Ltd Jan. 30, 2015 - April 1, 2015
Bill Bertrand's trades of Adaptimmune Therapeutics PLC's stock


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2025-08-29 2025-08-28
PrS Proposed sale
67,585
57.12
US$1,329,352 		67,585 57.12 US$1,329,352
2025-08-29 2025-08-28
S Sale
35,557 -20.8%
441.28
US$3,823,337 		35,557 -20.8% 441.28 US$3,823,337
2025-01-17 2025-01-17
PrS Proposed sale
63,326
324.78
US$319,482 		63,326 324.78 US$319,482
2025-01-17 2025-01-17
S Sale
5,584 -42.6%
0.58
US$3,243 		5,584 -42.6% 0.58 US$3,243
2025-01-15 2025-01-15
PrS Proposed sale
9,803
0.57
US$5,635 		9,803 0.57 US$5,635
2025-01-15 2025-01-15
S Sale
9,803 -41.6%
0.57
US$5,635 		9,803 -41.6% 0.57 US$5,635
2025-01-15 2025-01-13
PrS Proposed sale
9,739
0.59
US$5,726 		9,739 0.59 US$5,726
2025-01-15 2025-01-13
S Sale
5,471 -41.8%
0.59
US$3,216 		5,471 -41.8% 0.59 US$3,216
2025-01-15 2025-01-13
S Sale
4,268 -42.2%
0.59
US$2,509 		4,268 -42.2% 0.59 US$2,509
2024-01-17 2024-01-17
S Sale
13,599 -40.2%
0.67
US$9,152 		13,599 -40.2% 0.67 US$9,152
2024-01-17 2024-01-17
S Sale
5,309 -40.5%
0.67
US$3,573 		5,309 -40.5% 0.67 US$3,573
2024-01-17 2024-01-16
S Sale
4,681 -40.0%
0.79
US$3,698 		4,681 -40.0% 0.79 US$3,698
2024-01-12 2024-01-12
S Sale
5,220 -39.9%
0.85
US$4,458 		5,220 -39.9% 0.85 US$4,458
2024-01-12 2024-01-11
S Sale
4,009 -39.6%
0.84
US$3,354 		4,009 -39.6% 0.84 US$3,354
2023-01-17 2023-01-17
S Sale
4,440 -37.9%
1.86
US$8,250 		4,440 -37.9% 1.86 US$8,250
2023-01-12 2023-01-12
S Sale
4,973 -38.0%
1.71
US$8,484 		4,973 -38.0% 1.71 US$8,484
2023-01-12 2023-01-11
S Sale
3,843 -38.0%
1.75
US$6,713 		3,843 -38.0% 1.75 US$6,713
2023-01-04 2023-01-04
S Sale
3,584 -38.3%
1.69
US$6,071 		3,584 -38.3% 1.69 US$6,071
2022-01-18 2022-01-18
S Sale
4,368 -37.3%
3.19
US$13,942 		4,368 -37.3% 3.19 US$13,942
2022-01-13 2022-01-12
S Sale
2,248 -37.5%
3.54
US$7,967 		2,248 -37.5% 3.54 US$7,967
2022-01-13 2022-01-11
S Sale
3,770 -37.3%
3.56
US$13,409 		3,770 -37.3% 3.56 US$13,409
2022-01-05 2022-01-04
S Sale
3,490 -37.3%
4.06
US$14,184 		3,490 -37.3% 4.06 US$14,184
2021-01-12 2021-01-12
S Sale
2,234 -37.2%
6.15
US$13,744 		2,234 -37.2% 6.15 US$13,744
2021-01-05 2021-01-04
S Sale
3,499 -37.4%
5.33
US$18,642 		3,499 -37.4% 5.33 US$18,642
2020-12-15 2020-12-14
B Purchase
207,000 +266.0%
0.69
US$143,824 		207,000 +266.0% 0.69 US$143,824
2020-01-15 2020-01-14
S Sale
2,397 -39.9%
5.13
US$12,308 		2,397 -39.9% 5.13 US$12,308
2020-01-07 2020-01-06
S Sale
3,731 -39.8%
1.20
US$4,477 		3,731 -39.8% 1.20 US$4,477
2019-01-16 2019-01-14
S Sale
2,271 -37.8%
5.37
US$12,194 		2,271 -37.8% 5.37 US$12,194